Megan Ishibashi, DPM
Podiatrist · Los Angeles, CANPI 1093210627
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (35.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Arthrex at 46.1% of the total. Reporting peaked in 2022 at $4,588 and has fallen 95.7% since, to $198 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $185.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$5K
- Evolution Surgical, Inc$2K
- Paragon 28, Inc.$2K
- Stryker$1K
- Boston Scientific$142
- Paratek Pharmaceuticals, Inc.$125
- plus $286 from 4 others
What the payments were for
- Travel & lodging$3,58635%
- Food & beverage$2,99529%
- Education$3,60035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 16 | $4,695 |
| Evolution Surgical, Inc | 10 | $2,020 |
| Paragon 28, Inc. | 9 | $1,504 |
| Stryker | 14 | $1,409 |
| Boston Scientific | 1 | $142 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Nevro Corp. | 1 | $104 |
| Saxum Surgical, Inc. | 1 | $102 |
| Novastep Inc. | 1 | $53 |
| Avita Medical Americas, LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Portfolio$1,385
- STAR$340
- ORTHOLOC 3DI$173
- ORTHOLOC 2 LAPIFUSE$138
- PROSTEP MICA$133
- NUZYRA$125
- PROPHECY$114
- ACTISHIELD CF$112
- PROstep$108
- Omnia$104
How this compares
$10,181 in reported general payments places this provider in the 90th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 50 | $1,179 |
| Econazole Nitrate | 20 | $723 |
| Terbinafine Hcl | 16 | $77 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Los Angeles
- David ArmstrongLos Angeles$695K
- Charles AnanianLos Angeles$69K
- Edward KimLos Angeles$48K
- Benjamin McGrathLos Angeles$25K
- Laura ShinLos Angeles$20K
- Renato SousaLos Angeles$14K
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.